The importance of release of proinflammatory cytokines, ROS, and NO in different stages of colon carcinoma growth and metastasis after treatment with cytotoxic drugs

Oncology Research

Volumn 18, Issue 9, 2010, Pages 419-436

  Paduch, Roman ^a   Kandefer Szerszeń, Martyna ^a   Piersiak, Tomasz ^a  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

Author keywords

Coculture; Colon carcinoma; Cytotoxic drugs; Nitric oxide; Proinflammatory cytokines; Reactive oxygen species

Indexed keywords

CYTOKINE; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; IRINOTECAN; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CELL ADHESION; CELL INTERACTION; CELL STRAIN HT29; COCULTURE; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; HUMAN CELL; METASTASIS; MICROENVIRONMENT; MONOCULTURE; MYOFIBROBLAST; PRIORITY JOURNAL; SPHEROID CELL;

EID: 77952346645     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504010X12671222663593     Document Type: Article

References (48)

1. Partyka, S.; Ajani, J. Chemotherapy of colorectal cancer. Curr. Treat. Options Gastroenterol. 2:38-48; 1999.
2. Brandi, G.; Pantaleo, M. A.; Calabrese, C.; Di Battista, M.; Poggi, R.; Bajetta, E.; Biasco, G. Complete remission of primary colon cancer in a metastatic patient treated with CPT-11 plus capecitabine. Int. J. Colorectal Dis. 19: 599-602; 2004.
3. Adlard, J. W.; Richman, S. D.; Seymour, M. T.; Quirke, P. Prediction of the response of colorectal cancer to systemic therapy. Lancet Oncol. 3:75-82; 2002.
4. Fujishima, H.; Kikuchi, I.; Miyanaga, O.; Ueda, A.; Baba, E.; Mitsugi, K.; Harada, M.; Nakano, S. Phase I study of CPT-11 and bolus 5-FU/l-leucovorin in patients with metastatic colorectal cancer. Int. J. Clin. Oncol. 9:92-97; 2004.
5. Reina, J. J.; Aparicio, J.; Salvador, J.; Puerto Pica, J. M.; Rueda, A.; Lorenzo, A.; de la Puente, C. G.; Borrega, P.; Moreno-Nogueira, J. A. A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metatastatic colorectal cancer. Cancer Chemother. Pharmacol. 52: 339-345; 2003.
6. Sastre, J.; Paz-Ares, L.; Carcas, A.; Alfonso, R.; Grávalos, C.; Frías, J.; Guerra, P.; Pronk, L.; Cortés-Funes, H.; Díaz-Rubio, E. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumors. Cancer Chemother. Pharmacol. 55:453-460; 2005.
7. Apte, R. N. Interleukin-1-a major pleiotropic cytokine in tumor-host interactions. Semin. Cancer Biol. 12:277-290; 2002.
8. Ashwood, P.; Harvey, R.; Verjee, T.; Wolstencroft, R.; Thompson, R. P. H.; Powell, J. J. Competition between IL-1, IL-1ra and TGF-β modulates the response of the ELA4.NOB-1/CTLL bioassay: Implications for clinical investigations. Inflamm. Res. 53:60-65; 2004.
9. Eutamene, H.; Theodorou, V.; Fioramonti, J.; Bueno, L. Implication of NK1 and NK2 receptors in rat colonic hypersecretion induced by interleukin 1β: Role of nitric oxide. Gastroenterology 109:483-489; 1995.
10. Apte, R. N.; Dotan, S.; Elkabets, M.; White, M. R.; Reich, E.; Carmi, Y.; Song, X.; Dvozkin, T.; Krelin, Y.; Voronov, E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 25:387-408; 2006.
11. Lewis, A. M.; Varghese, S.; Xu, H.; Alexander, H. R. Interleukin-1 and cancer progression: The emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J. Translat. Med. 4:48-59; 2006.
12. Schneider, M. R.; Hoeflich, A.; Fischer, J. R.; Wolf, E.; Sordat, B.; Lahm, H. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett. 151:31-38; 2000.
13. Yamamoto, T.; Matsuda, T.; Junicho, A.; Kishi, H.; Saatcioglu, F.; Muraguchi, A. Cross-talk between signal transducer and activator of transcription 3 and estrogen receptor signaling. FEBS Lett. 486:143-148; 2000.
14. Atreya, R.; Neurath, M. F. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin. Rev. Allergy Immunol. 28:187-195; 2005.
15. Jabłońska, E. Release of soluble IL-6 receptor (IL-6sR) in comparison with release of soluble TNF receptors (sTNFRs) by PMNs and WBC derived from breast cancer patients. Cancer Lett. 119:79-85; 1997.
16. Medvedev, A. E.; Espevik, T.; Ranges, G.; Sundan, A. Distinct roles of the two tumor necrosis factor (TNF) receptors in modulating TNF and lymphotoxin α effects. J. Biol. Chem. 271:9778-9784; 1996.
17. Viac, J.; Vincent, C.; Palacio, S.; Schmitt, D.; Claudy, A. Tumour necrosis factor (TNF) soluble receptors in malignant melanoma: Correlation with soluble ICAM-1 levels. Eur. J. Cancer 32A:447-449; 1996.
18. Obrador, E.; Navaerro, J.; Mompo, J.; Asensi, M.; Pellicer, J. A.; Estrela, J. M. Regulation of tumour cell sensitivity to TNF-induced oxidative stress and cytotoxicity: Role of gluthatione. Biofactors 8:23-26; 1998.
19. Goossens, V.; De Vos, K.; Vercammen, D.; Steemans, M.; Vancompernolle, K.; Fiers, W.; Vandenabeele, P.; Grooten, J. Redox regulation of TNF signalling. Biofactors 10:145-156; 1999.
20. Paduch, R.; Walter-Croneck, A.; Zdzisińska, B.; Szuster-Ciesielska, A.; Kandefer-Szerszeń, M. Role of reactive oxygen species (ROS), metalloproteinase-2 (MMP-2) and interleukin-6 (IL-6) in direct interactions between tumour cell spheroids and endothelial cell monolayer. Cell Biol. Int. 29:497-505; 2005.
21. Lorenz, B.; Schlüter, T.; Bohnensack, R.; Pergande, G.; Müller, W. E. G. Effect of flupirtine on cell death of human umbilical vein endothelial cells induced by reactive oxygen species. Biochem. Pharmacol. 56:1615-1624; 1998.
22. Yen, C. H.; Hsieh, C. C.; Chou, S. Y.; Lau, Y. T. 17β-estradiol inhibits oxidized low density lipoprotein-induced generation of reactive oxygen species in endothelial cells. Life Sci. 70:403-413; 2001.
23. Lala, P. K.; Chakraborty, Ch. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 3:149-156; 2001.
24. Rao, Ch. V. Nitric oxide signalling in colon cancer chemoprevention. Mutat. Res. 555:107-119; 2004.
25. Kunz-Schughart, L. A.; Kreutz, M.; Knuechel, R. Multicellular spheroids: A three-dimensional in vitro culture system to study tumor biology. Int. J. Exp. Pathol. 79: 1-23; 1998.
26. Paduch, R.; Kandefer-Szerszeń, M. Vitamin D, tamoxifen and β-estradiol modulate breast cancer growth and interleukin- 6 and metalloproteinase-2 production in threedimensional co-cultures of tumor cell spheroids with endothelium. Cell Biol. Toxicol. 21:247-256; 2005.
27. Colowick, S. P.; Kaplan, N. O. Methods in enzymology. In: Di Sabato, G.; Everse, J.; eds. Phagocytosis and cell-mediated cytotoxicity (Vol. 132, Part J). Orlando, FL: Academic Press; 1986:410-417.
28. Brubacher, J. L.; Bols, N. C. Chemically de-acetylated 2′ ,7′ -dichlorodihydrofluorescein diacetate as a probe of respiratory burst activity in mononuclear phagocytes. J. Immunol. Methods 251:81-91; 2001.
29. Haklar, G.; Sayin-Özveri, E.; Yüksel, M.; Aktan, A. Ö .; Yalçin, A. S. Different kinds of reactive oxygen and nitrogen species were detected in colon and breast tumors. Cancer Lett. 165:219-224; 2001.
30. Lu, F. Reactive oxygen species in cancer, too much or too little? Med. Hypotheses 69:1293-1298; 2007.
31. Bize, I. B.; Oberley, L. W.; Morris, H. P. Superoxide dysmutase and superoxide radical in Morris hepatomas. Cancer Res. 40:3686-3652; 1980.
32. Van Driel, B. E.; Van Noorden, C. J. Oxygen insensitivity of the histochemical assay of glucose-6-phosphate dehydrogenase activity for the discrimination between nonmalignant and malignant cells. J. Histochem. Cytochem. 47: 575-582; 1999.
33. Offner, F. A.; Schiefer, J.; Wirtz, H.-Ch.; Bigalke, I.; Pavelka, M.; Hollweg, G.; Ensinger, Ch.; Klosterhalfen, B.; Mittermayer, Ch.; Kirkpatrick, Ch. J. Tumour-cell-endothelial interactions: Free radicals are mediators of melanoma-induced endothelial cell damage. Virchows Arch. 428:99-106; 1996.
34. Millet, A.; Bettaieb, A.; Renaud, F. Inluence of the nitric oxide donor glyceryl trinitrate on apoptotic pathwaysin human colon cancer cells. Gastroenterology 123:235-246; 2002.
35. Kim, P. K. M.; Zamora, R.; Petrosko, P.; Billiar, T. R. The regulatory role of nitric oxide in apoptosis. Int. Immunopharmacol. 1:1421-1441; 2001.
36. Koren, R.; Rocker, D.; Kotestiano, O.; Liberman, U. A.; Ravid, A. Synergistic anticancer activity of 1,25-dihydroxyvitamin D3 and immune cytokines: The involvement of reactive oxygen species. J. Steroid Biochem. Mol. Biol. 73:105-112; 2000.
37. Sung, J.-Y.; Hong, J.-H.; Kang, H.-S.; Choi, I.; Lim, S.-D.; Lee, J.-K.; Seok, J.-H.; Lee, J.-H.; Hur, G.-M. Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis. Immunopharmacology 47:35-44; 2000.
38. Bellone, G.; Smirne, C.; Mauri, F. A.; Tonel, E.; Carbone, A.; Buffolino, A.; Dughera, L.; Robecchi, A.; Pirisi, M.; Emanuelli, G. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: Implications for survival. Cancer Immunol. Immunther. 55: 684-698; 2006.
39. Deakin, A. M.; Payne, A. N.; Whittle, B. J. R.; Moncada, S. The modulation of IL-6 and TNF-α release by nitric oxide following stimulation of J774 cells with LPS and IFN-γ. Cytokine 7:408-416; 1995.
40. Logan, R. M.; Stringer, A. M.; Bowen, J. M.; Yeoh, A. S.-J.; Gibson, R. J.; Sonis, S. T.; Keefe, D. M. K. The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs. Cancer Treat. Rev. 33:448-460; 2007.
41. Kishida, O.; Miyazaki, Y.; Murayama, Y.; Ogasa, M.; Miyazaki, T.; Yamamoto, T.; Watabe, K.; Tsutsui, S.; Kiyohara, T.; Shimomura, I.; Shinomura, Y. Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemoter. Pharmacol. 55:584-594; 2005.
42. Sentürker, S.; Tschirret-Guth, R.; Morrow, J.; Levine, R.; Shacter, E. Induction of apoptosis by chemotherapeutic drugs without generation of reactive oxygen species. Arch. Biochem. Biophys. 397:262-272; 2002.
43. Gao, F.; Horie, T. A synthetic analog of prostaglandin E1 prevents the production of reactive oxygen species in the intestinal mucosa of methotrexate-treated rats. Life Sci. 71:1091-1099; 2002.
44. Vibet, S.; Goupille, C.; Bougnoux, P.; Steghens, J.-P.; Goré, J.; Mahéo, K. Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines though loss of glutathione peroxidase (GPx1) response. Free Radic. Biol. Med. 44:1483-1491; 2008.
45. Hwang, I. T.; Chung, Y. M.; Kim, J. J.; Chung, J. S.; Kim, B. S.; Kim, H. J.; Kim, J. S.; Yoo, Y. D. Drug resistance to 5-FU linked to reactive oxygen species modulator 1. Biochem. Biophys. Res. Commun. 359:304-310; 2007.
46. Kallio, A.; Zheng, A.; Dahllund, J.; Heiskanen, K. M.; Härkönen, P. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 10: 1395-1410; 2005.
47. Logan, R. M.; Stringer, A. M.; Bowen, J. M.; Gibson, R. J.; Sonis, S. T.; Keefe, D. M. K. Serum levels of NF-κB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol. Ther. 7:1139-1145; 2008.
48. Goto, S.; Okutomi, T.; Suma, Y.; Kera, J.; Soma, G.-I.; Takeuchi, S. Induction of tumor necrosis factor by a camptothecin derivative, irinotecan, in mice and human mononuclear cells. Anticancer Res. 16:2507-2511; 1996.